Various Invariant NKT (iNKT) cell ligands have been shown as potent adjuvants in boosting T cell reactivates to antigens on professional APC. Non-professional APC, such as T cells, also co-expressing MHC class I and CD1d, have been unattractive cell vaccine carriers due to their poor immunogenicity. Here, we report that T cells as well as T cell lymphoma can efficiently generate antigen-specific cytotoxic T lymphocytes (CTL) responses in mice in vivo, when formulated to present iNKT ligand a-galactosylceramide (aGC) on their surface CD1d. Vaccination with aGC-pulsed EG-7 T-cell lymphoma induced tumor-specific CTL response and suppressed the growth of EG-7 in a CD8 T cell-dependent manner. Injection of aGC-loaded CD4 T cells in mice efficiently activated iNKT cells in vivo. While T cells loaded with a class I-restricted peptide induced proliferation but not effector differentiation of antigen-specific CD8 T cells, injection of T cells co-pulsed with aGC strongly induced IFNc and Granzyme B expression in T cells and complete lysis of target cells in vivo. Presentation of aGC and peptide on the same cells was required for optimal CTL response and vaccinating T cells appeared to directly stimulate both iNKT and cytotoxic CD8 T cells. Of note, the generation of this cytotoxic T cell response was independent of IL-4, IFNc, IL-12, IL-21 and costimulation. Our data indicate that iNKT cell can license a non-professional APC to directly trigger antigen-specific cytotoxic T cell responses, which provides an alternative cellular vaccine strategy against tumors.
Introduction
CD1d-restricted invariant NKT cells (iNKT) recognize glycolipid antigens presented on non-classical MHC class I-like molecule, CD1d. Recent studies revealed a crucial role of iNKT cells in the host defense against pathogens and tumors through direct interaction with microbial antigens or indirect activation. 1 Moreover, iNKT cell acts as a bridge between innate and acquired immune system by regulating T cell activation and function. For instance, iNKT ligands have been shown with strong potency in enhancing T cell responses to soluble protein antigens or tumor antigens presented by professional antigenpresenting cells (APC). Co-administration of a-galactosylceramide (aGC) and protein antigens generates the antigen-specific CD4 T and CD8 T cell immunity in vivo. 2, 3 The generation of antigenspecific adaptive immunity depends on the activation and maturation of dendritic cells (DC) after aGC injection which triggers IFNc and TNFa expression from iNKT cells. 2, 4 Costimulation such as CD40 and CD80/CD86 is required for the T cell immunity in this case. 4 Furthermore, injection of DCassociated aGC induces the activation and expansion of iNKT cells and NK cells in vivo in tumor patients. 5, 6 Non-professional APC in immune system, such as T cells, express both MHC class I and CD1d. The expression of MHC class I on these cells may allow them to be protected from NK cellmediated cytotoxic attack through interaction with inhibitory receptors. 7 The role of CD1d expression on peripheral T cells in iNKT cell biology is not yet clear, although it is well established that CD1d expression on thymic T cells is essential for positive selection of iNKT cell. 8, 9 DC has been shown to be the most efficient APC for iNKT cell priming when aGC was injected as a soluble form, while other types of cell expressing CDld suppress iNKT cell activation in this condition. 10 In addition to DC, vaccination with B cells copulsed with aGC and tumor-derived peptide generates an efficient anti-tumor CD8 T cell response in several murine tumor models. 11 Furthermore, our recent study showed that autologous B lymphoma vaccine, manipulated to present aGC, can establish memory anti-tumor T cell immunity. 12 Of note, Shimizu et al.
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recently showed that non-professional APCs, such as T and NK cells, can stimulate iNKT cell activation when they presented aGC in a cell-associated form. 11, 13 They also showed that tumors lacking costimulatory molecules, such as B16 melanoma and EL4 thymoma, can induce the activation of iNKT cells and NK cells in vivo when formulated to present aGC. These observations together raise an interesting question if iNKT ligand-loaded nonprofessional APC could act as an efficient APC in generating CD8 T cell response against the peptides loaded on their surface MHC class I. If this is true, it might be possible to use tumor cell itself or pathogen-infected cells to generate tumor-or pathogen-specific cytotoxic T cell immunity, which would be much easier, costeffective and practical in clinical settings.
Therefore in the present study, we tested whether conventional T cells-as a surrogate CD1d-expressing non-professional APCcan actively interact with iNKT cells and CD8 T cells in the presence of an iNKT cell ligand and MHC class I-restricted peptide. Our results showed an efficient activation of iNKT cells and antigen-specific CD8 T cells in mice vaccinated with T cells presenting both aGC and peptide on the same cells, which induced an effective immunity against microbial infection and tumor. Moreover, vaccination with aGC-pulsed thymoma generated a tumor-specific cytotoxic T cell response in vivo. Thus, in the presence of iNKT cell help, non-professional APC, such as T cells, can stimulate cytotoxic T cell function, providing an alternative means of cell vaccination method.
Results

Vaccination with aGC-loaded EG-7 generates CD8
+ T celldependent antitumor activity. We first asked whether vaccination with tumor cells of T cell origin can trigger anti-tumor activity, when manipulated to present aGC. To track tumor-specific T cell responses more efficiently in vivo, we employed ovalbuminexpressing EL4 thymoma (EG-7) as our tumor model. To address protective antitumor activity by vaccination with aGC-loaded EG-7, we vaccinated mice with irradiated EG-7 co-cultured with 1 mg/mL of aGC overnight. EG-7 cells incubated with the same volume of solvent (5 ml/mL of 0.5% polysorbate) were used as control (EG-7/veh). After extensive washing, these cells were i.v. injected into syngenic naïve mice. These mice were subcutaneously implanted with live EG-7 and the tumor volume and survival were monitored daily. Mice were sacrificed when tumor diameters reached 20 mm. As depicted in Figure 1A and B, the vaccination with EG-7/aGC significantly reduced the growth of solid tumors and induced prolonged survival in comparison to those of EG-7/veh group. Tumors affect myelopoiesis and induce the expansion of CD11b + Gr-1 + Figure 1 . Vaccination with aGC-loaded EG-7 generated preventive antitumor activity. (A-D) EG-7 cells were co-cultured overnight with 1 mg/ml of aGC (EG-7/aGC) or vehicle followed by irradiation (50 Gy). C57BL/6 mice (n = 7 per group) were vaccinated with EG-7/veh, EG-7/aGC or untreated (Nil). One week later, all mice were subcutaneously injected with 1 ¾ 10 6 live EG-7 cells and the survival (A) and tumor size (B) were checked. (C) At the 3 weeks later, splenocytes were isolated from tumor bearing mice and analyzed by flow cytometer after staining with anti-CD11b, anti-Gr1, anti-CD19, anti-CD4 and anti-CD8 antibodies. (D) Splenocytes were restimulated with SIINFEKL in the presence of Golgi-Plug for 5 h before intracellular staining of IFNc on OVA specific T cells. *p , 0.05, **p , 0.005, p values were calculated with 2-way ANOVA (A), Kaplan-Meier method (B) or Student's t-tests (C and D) in comparison with the EG-7/veh group. myeloid-derived suppressor cell (MDSC) in the bone marrow, blood, spleen.
14 Of note, we also observed a great decrease of CD11b + Gr-1 + population in the spleen of EG-7/aGC vaccinated mice (, 4%) compared with that of EG-7/veh group (. 20%) (Fig. 1C) , another indicative of antitumor activity induced by the vaccination. Importantly, mice vaccinated with EG-7/aGC showed higher numbers of CD8 + T cells producing IFNc upon SIINFEKL stimulation (Fig. 1D) . These results overall indicate the induction of anti-tumor activity as well as tumor-specific CD8 + T cell responses upon the vaccination with EG-7/aGC in vivo.
Therefore, we next examined if the observed anti-tumor activity by vaccination with EG-7/aGC depends on CD8 + T cells. We injected anti-CD8 depleting antibody into the vaccinated mice before we transplanted live EG-7 cells into them. Depletion of CD8 + cells greatly decreased the protective anti-tumor activity by vaccination with EG-7/aGC ( Fig. 2A) and the survival of vaccinated mice (Fig. 2B) . Taken together, these results indicate that antitumor immunity generated by aGC-loaded EG-7 is, at least in part, mediated by CD8 T cells.
Vaccination with aGC-loaded EG-7 induces ova-specific cytotoxic responses. Our EG-7 tumor models ( Fig. 1 ) and CD8 depletion experiment (Fig. 2) raised a hypothesis that tumor cells of T cell origin, when they present iNKT ligand, are able to induce cytotoxic T cell response specific for endogenous tumor antigens. To test our hypothesis, we co-cultured EG-7 cells with aGC or vehicle before being irradiated (EG-7/aGC and EG-7/ veh, respectively). To increase the expression of peptide/MHC-I complex, EG-7 cells were first pre-treated with IFNc. One week after vaccination, we performed an in vivo CTL assay to determine the antigen-specific cytotoxicity against SIINFEKL-loaded syngenic splenocytes 11 . When injected into naïve syngenic mice, EG-7/aGC resulted in an evident peptide-loaded target cell lysis whereas EG-7/veh did not ( Fig. 3A; -0.37% and 72.8% lysis, respectively). To examine if CD8 + T cells in the vaccinated mice directly kill target cells in an antigen-specific way, we performed an in vitro CTL assay with purified CD8 + T cells from the vaccinated mice by analyzing caspase-3 activation in the target cells. As depicted in Figure 3B , the CD8 + T cells from the EG-7/aGC vaccinated mice induced a significantly higher percentage of caspase-3 cleavage in the target cells than those from the EG-7/veh vaccinated mice. In addition, the effective target lysis in EG-7/ aGC-vaccinated mice was associated with increased antigenspecific IFNc + granzyme B + CD8 T cells in the spleen (Fig. 3C) . To further characterize the antigen-specific CD8 T cells, we adoptively transferred CFSE-labeled OT-I T cells (CD45.2) into congenic mice (CD45.1). The recipients were vaccinated with either EG-7/veh or EG-7/aGC and CD45.2 + cells were analyzed five days later. OT-I T cells in mice vaccinated with EG-7/veh underwent an extensive proliferation, but expressed little IFNc (, 10%) or granzyme B (, 3%). By contrast, significantly higher population of OT-I T cells in EG-7/aGC-vaccinated mice expressed IFNc (. 50%) and granzyme B (. 8%) (Fig. 3D) . Taken together, these data demonstrate that aGC-loaded EG-7 thymoma induced tumor-specific CD8 + T cells to differentiate into cytotoxic effector T cells expressing high levels of IFNc and granzyme B in vivo.
aGC induces cytotoxic T cell response to T cell-associated antigens. Our study thus far showed that, with help of aGC, tumors of T cell origin can trigger tumor-specific cytotoxic T cell responses. Therefore we next asked if conventional T cells can also act as antigen presenting cells and trigger cytotoxic T cell responses in vivo, when formulated to present aGC. A previous study by Shimizu et al. showed that T cells, purified by negative selection using magnetic beads and when loaded with aGC, stimulate iNKT cells in vivo. 13 To further assess iNKT cell activation by T cells, we first sorted (Fig. 4A) . The sorted cells were loaded with aGC (T/aGC) or with vehicle (T/veh) and were i.v. injected into syngenic naïve mice. When we analyzed splenocytes six hours after the injection, we observed that CD1d-tetramer + cells in mice receiving T/aGC produced IFNc + whereas the same population in mice receiving T/veh did not produce IFNc (Fig. 4B) . Therefore CD4 + T cells efficiently triggered iNKT cell activation in vivo when they were manipulated to present aGC.
We next asked whether T/aGC can induce antigen-specific cytotoxicity when they were additionally pulsed with MHC class I-restricted peptide. SIINFEKL peptide (1ng/mL) was added to T cells in the last one hour when they were incubated with aGC or vehicle (T/aGC/pep and T/veh/pep, respectively). After extensive washing, C57BL/6 mice were immunized with T/veh/ pep or T/aGC/pep. One week later, we performed an in vivo CTL assay to determine the antigen-specific cytotoxicity against SIINFEKL-loaded syngenic splenocytes. Mice vaccinated with T/aGC/pep showed complete lysis of target cells while mice vaccinated with T/veh/pep did not (Fig. 4C) . To analyze whether T/veh/pep vaccination results in cytotoxic function of antigen-specific CD8 T cells, we isolated CD8 + T cells from OT-I mice, labeled them with 10 mM CFSE before transferring into C57BL/6 mice, which were then vaccinated with T/veh/pep or T/aGC/pep. When OT-I cells in the spleen of recipients were analyzed 48 hours after vaccination, both types of T cell vaccination induced the proliferation of OT-I T cells in vivo, although the proportion of T cells that had undergone over five times of division was higher in mice receiving T/aGC/pep vaccination than those with T/veh/pep (Fig. 4D, upper panels) . More importantly, OT-I T cells in mice vaccinated with T/aGC/ pep displayed remarkably higher expression of granzyme B and IFNc compared with those in T/veh/pep-vaccinated mice (Fig. 4D, middle and lower panels) . These data demonstrate that in response to an antigen on CD4 T cells as a non-professional APC, although antigen-specific CD8 T cells could proliferate, their functional differentiation into cytotoxic cells could only occurr in the presence of iNKT cell 'help'.
T/aGC/Pep vaccination confers protection against Listeria monocytogenes and melanoma. We next tested whether the cytotoxic T cell response generated by T/aGC/pep vaccination is effective enough in suppressing the growth of intracellular bacteria and tumor in an antigen-specific manner. We first employed L. monocytogenes infection model since clearance of this bacterium is largely dependent on CD8 T cell response. Mice were vaccinated with T/aGC, T/aGC/pep or peptide-pulsed dendritic cells (DC/pep) as a control. Ten days later, the vaccinated mice were i.v. injected with L. monocytogenes expressing OVA and the bacterial burden in the spleen and liver was measured. As expected, mice vaccinated with DC/pep showed significantly lower bacterial burden in both spleen and liver compared with non-vaccinated mice (Fig. 5A) . Compared with non-vaccinated group, mice vaccinated with T/aGC showed slightly lower bacterial burden, especially in the liver. In contrast, mice vaccinated with T/aGC/pep also showed significantly lower bacterial burden in both organs, which is comparable to those of DC/pep-vaccinated mice (Fig. 5A) . 
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To assess if the vaccinated mice were also resistant to tumor growth, we i.v. injected OVA-expressing B16 melanoma cells into the vaccinated mice. Fourteen days later, we counted tumor foci in the lung of recipients. Compared with non-vaccinated mice, mice vaccinated with T/aGC had less tumor foci (Fig. 5B) . On the other hand, fewer tumor foci were found in mice vaccinated with T/aGC/pep or DC/pep (Fig. 5B) . Intracellular staining of peripheral blood mononuclear cells after peptide restimulation revealed that both DC/pep and T/aGC/pep vaccinations efficiently induced peptide-specific IFNc-producing CD8 T cells (Fig. 5C) , which correlated well with anti-Listeria and antimetastatic activity in the vaccinated mice. Collectively, these data demonstrate that vaccination with T/aGC/pep established protective immunity against intracellular bacteria and tumor in a peptide-specific manner.
T cells simultaneously presenting iNKT and class I-restricted ligands directly induce antigen-specific cytotoxicity. We next sought to elucidate the mode of action in the efficient induction of peptide-specific cytotoxicity during T/aGC/pep vaccination. When we vaccinated CD1d-deficient mice with T/aGC/pep, we did not observe peptide-specific cytotoxicity in our in vivo CTL assay (Fig. 6A) . Therefore, the antigen-specific cytotoxicity elicited by T/aGC/pep requires iNKT cells in vivo.
Next we asked if vaccinated T cells directly stimulate CD8 T cells or require host APC. We utilized bm-1 mouse whose cells are able to load SIINFEKL onto their MHC I, but the resulting complex cannot be recognized by OT-I TCR due to a mutation in the H-2K region. 15 In this experiment, vaccination with T/aGC/pep using T cells from bm-1 mice failed in induction of antigen-specific target cell lysis (Fig. 6B) , indicating that appropriate MHC/peptide complex on the vaccinating T cells is essential and that they probably directly primed OT-I cells.
Since aGC and class I peptide are both presented by the same T cells, this suggests that iNKT ligand may provide a "dangerous" signal to the immune system. To test this hypothesis, C57BL/6 mice were vaccinated with T/pep in combination with either soluble aGC (2mg, i.p.) or T/aGC. In mice vaccinated with the former combination, little peptide-specific CTL was generated (Fig. 6C, 13 .4% vs. 97.2% lysis in T/aGC/pep-vaccinated mice). Moreover, mice vaccinated with T/aGC plus T/pep only showed a moderate peptide-specific CTL, significantly less efficient than that of T/aGC/pep (Fig. 6C, 47 .2% lysis vs 97.2% in T/aGC/pepvaccinated mice). Thus, these data demonstrate that the vaccinating T cells act as direct stimulators for both iNKT and CD8 T cells in vivo and that presentation of aGC and peptide by the same T cell is the most efficient regimen in generating antigen-specific CTL.
Cytokine and costimulation requirements in the CTL response elicited by T/aGC/Pep. Upon activation, iNKT cells promptly produce a wide range of cytokines including IL-4 and IFNc. IL-4 produced by activated iNKT cells was shown to promote CD8 T cell proliferation. 16 IFNc and IL-12 produced upon iNKT and DC interaction mediate anti-tumor activity. 17, 18 Recent studies showed that IL-21 is produced by iNKT cells upon TcR stimulation and regulates the activation and expansion of iNKT cells. 19, 20 Therefore, we asked whether these cytokines produced after iNKT cell activation had any role in the generation of CTL in our T cell vaccine model. We vaccinated IL-4
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2/2 or IL-21 2/2 mice with T/aGC/pep and performed in vivo CTL assay. As depicted in Figure 7A , we observed a complete peptide-specific CTL activity in all of cytokine-deficient mice we tested. Thus, none of these cytokines is necessary in the generation of CTL activity by the T cell vaccine. Costimulatory signals are essential in regulating the activation and expansion of iNKT cells. Moreover, CD28 and ICOS signals are required for the anti-tumor activity of activated iNKT cells such as cytotoxicity and anti-metastatic activity. 2, [21] [22] [23] Activated T cells express CD80 and CD86 and may regulate immune response through T:T interaction. 24 ,25 Therefore we asked whether these costimulatory factors were necessary for the induction of CTL in our model. T cells were isolated from C57BL/6(WT), B7 and loaded with aGC and SIINFEKL ex vivo. The T/aGC/pep were injected into WT mice and in vivo CTL assay was performed. As depicted in Figure 7B , we observed a normal target cell lysis in mice vaccinated with costimulation-deficient T cells. Thus, the induction of peptide-specific cytotoxicity by the T cell vaccine does not require B7 and B7h costimulation.
Discussion
In the present study, we showed that vaccination with conventional CD4 T cells presenting both CD1d-aGC and MHC class I-restricted peptide triggered iNKT cell activation and generated an antigen-specific cytotoxic T lymphocyte response in vivo. Mice receiving this novel T cell vaccine were resistant to L. monocytogenes infection as well as to tumor challenge in an antigen-dependent manner. Moreover, vaccination with aGCpulsed T cell lymphoma also induced CTL response specific for an endogenous tumor antigen. Mechanistic analyses indicate that the vaccinated T cells directly stimulated peptide-specific cytotoxic T cells and that the CTL responses induced by these 'T cell vaccines' were independent of cytokines such as IFNc, IL-12 and IL-21. Therefore T cells as well as tumors of T cell origin can act as antigen-presenting cells that efficiently trigger cytotoxic T cell responses, when they are formulated to stimulate iNKT cells in vivo. Dendritic cells loaded with various iNKT ligands are potent inducer of T cell immunity. We recently showed that B cells copulsed with aGC and class I peptide also induce antigen-specific CTL response in vivo as efficiently as well. 11 Moreover, our recent study showed that B lymphoma cells loaded with aGC elicited a strong protective immunity that is dependent on CD4 T cells. 12 However, it has been unclear whether non-professional APC in the presence of iNKT cell help could induce T cell effector function. In the present study, we found that CD8 T cells were activated by antigens presented by CD4 T cells and proliferated extensively. However, they did not produce significant amounts of IFNc or Granzyme B that are associated with cytotoxic effector function, indicating that CD4 T cells are not an efficient APC. It is possible that T cells, like other non-professional APC, do not express high levels of costimulatory molecules, which is required for CD8 T cell effector function. 26 We have also previously observed this type of non-productive activation in CD8 T cells reactive to a tissue antigen, which is mediated by PD-1-PDL1 interaction. 27 In the presence of aGC and hence iNKT "help," antigen-specific CD8 T cells were able to undergo effector differentiation by the CD4 T cell vaccine that results in protection against infection and tumor. Since iNKT ligands are either derived from infectious agents or induced during infection, their presence on non-professional APC may provide a "dangerous" signal to the immune system and, through iNKT cells, "license" a productive T cell activation and their effector differentiation.
How iNKT cell help CD8 cell effector differentiation remains unclear at this stage. After activation, iNKT cells promptly produce a wide range of cytokines which can further activate themselves and other immune cells including NK, DC, T and B cells. IFNc and IL-12 are critical mediators for T cell immunity. IFNc produced by iNKT cells and NK cells mediates antiangiogenic activity of aGC.
18 IL-12 produced by DC after interaction with iNKT cells is critical for inducing IFNc in iNKT cells. 17 However, in our T cell vaccine model, neither IFNc nor IL-12 was required for CTL generation. Recent studies suggest that IL-21 is a crucial cytokine for iNKT cell activation and function. 19, 20 However, an efficient induction of CTL response by our T cell vaccine in IL-21-deficient mice excludes the role of this cytokine in the generation of CTL response in our model. Moreover, although vaccinated T cells were found to directly stimulate iNKT and CD8 T cells, this action does not appear to require costimulation. We recently found that dendritic cells loaded with aGC induced iNKT cell activation in the absence of B7 and B7h (data not shown). It is unclear at this stage whether there is any signal in addition to TcR that is required for iNKT and CD8 T cell activation by our T cell vaccine.
Nonetheless, T cells loaded with an iNKT ligand serves as a potent cellular vaccination approach. A mild suppression of tumor growth and L. monocytogenes growth was observed in mice vaccinated with T/aGC, indicating that an effective innate immunity was induced. However, vaccination with T/aGC/pep was far more effective in eliciting CD8 T cell immunity and specifically suppressing tumor growth and L. monocytogenes growth, which was comparable to DC vaccination. Based on our results, we propose that T cells from individuals infected with T cell-tropic pathogens-such as HIV-could be used as a source of cellular vaccine for triggering pathogen-specific cytotoxic response. Notably, i.v. injection of irradiated EG-7 thymoma did not induce an OVA-specific CTL response; however, injection of aGC-loaded, irradiated EG-7 efficiently generated an OVA-specific CTL response. As a result, vaccination with aGCloaded, irradiated EG-7 induced a potent anti-tumor activity against challenge with live EG-7, which was CD8 + T celldependent. Therefore we propose that vaccination of aGC-loaded T lymphoma may result in the generation of tumor-specific CTL response.
Our finding is novel in that non-professsional APCs are also able to trigger cytotoxic T cell immunity with the help of iNKT cell. T cell is a major population in blood and can be easily expanded and cultured in vitro. Although resting human T cells express little CD1d, activated T cells as well as thymocytes in humans express CD1d on their surface. 28 Moreover, cutaneous T cell lymphomas in humans have been reported to express high levels of CD1D. 29 These observations suggest that our findings can be directly applicable in clinical settings. Therefore, tumors that are not professional APC in origin, especially thymoma and T lymphoma, could be used as efficient APC for cytotoxic T cell anti-tumor immunity when they are formulated to stimulate iNKT cells. Our T cell vaccine strategy will provide an alternative cellular vaccine regimen that can induce the efficient activation of both innate and adaptive immunity in vivo.
Materials and Methods
Mice. C57BL/6, OT-I, C57BL/6 bm1 (bm-1), IL-4 2/2 , IFNc
) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). B6.SJL mice (Ly5.1) were purchased from Taconic Farm. B7h 2/2 and B7B7h 2/2 mice were generated and backcrossed in our laboratory. 26, 30 CD1d 2/2 mice were bred in our animal facility. IL-21
2/2 mice were previously described 31 and bred in our animal facility. All mice were kept under specific pathogen-free conditions in our animal facility (MD Anderson Cancer Center). All animal studies were approved by the Institutional Animal Care and Use Committee of MD Anderson Cancer Center. In some experiments, CD4 T cells were isolated from CD1d 2/2 or bm-1 mice. Bone marrow-derived DCs were generated by culturing bone-marrow cells in the presence of GM-CSF and IL-4 for 6 d. Sorted T cells were co-cultured with aGC (1 mg/mL) or the same volume of solvent vehicle (5 ml/mL of 0.5% polysorbate) overnight. In some experiments, these cells were further incubated with SIINFEKL peptide for 1 h.
EG-7 cells were cultured in the presence of IFNc (100 ng/mL) for 48 h including overnight culture with aGC or vehicle as described above. These EG-7 cells were washed and irradiated with Cs source (50 Gy) before i.v. injected into syngenic mice.
CFSE-labeled OT-I adoptive transfer. Ovalbumin-specific CD8 T cells were isolated from the lymphoid cells of OT-I mice using anti-CD8 magnetic beads and AutoMacs (. 92% are Va2 + ). These cells were labeled with 10 mM of CFSE and i.v. transferred into C57BL/6 mice. In some experiment, Ly5.1 congenic mice were used as recipients. Recipient mice were i.v. injected with CD4 T cells or irradiated EG-7 cells formulated ex vivo with indicated conditions. Two to five days later, lymphoid cells from the spleen of recipient mice were isolated and cultured with 0.1 mg/mL SIINFEKL in the presence of GolgiPlug (1 mL/mL) for 5 h. These cells were stained with phycoerythrin (PE)-conjugated anti-Va2 Ab or PE-conjugated anti-Ly5.2 Ab before permeabilized and further stained with APC-conjugated anti-IFNc Ab or Alexa 647-conjugated anti-granzyme B Ab. Total 1 ¾ 10 6 events were collected and CFSE + PE + cells were gated and analyzed by FACS Calibur.
iNKT cell staining. For intracellular staining of IFNc in iNKT cells, splenocytes and liver mononuclear cells from mice injected with vehicle-pulsed T cells, aGC-loaded T cells were stained with PE-conjugated aGC-loaded/CD1d-tetramer together with FITCconjugated anti-CD19 Ab (for splenocytes) or FITC-conjugated anti-TCRβ Ab. These cells were permeabilized and stained with APC-conjugated anti-IFNc Ab. CD19 In vitro and vivo cytotoxic T lymphocytes response assay. The in vitro SIINFEKL-specific cytotoxic T lymphocytes response was measured using a caspase-3 cleavage assay. 32 In brief, CD8 T cells were isolated from the vaccinated mice by using anti-CD8 microbeads and magnetic activated cell sorting. Splenocytes from syngenic mice were used as target cells after labeled with DDAO-SE and 1 mg/mL peptide. The sorted CD8 T cells were cocultured with the target splenocytes at a 1:1 ratio for 2 h at 37°C. The cells were permeabilized and stained with PE-conjugated anti-cleaved caspase-3 antibody. The percentage of cleaved caspase-3-positive cells among DDAO-SE-labeled target cells were analyzed by flow cytometry. The in vivo SIINFEKL-specific cytolytic activity of CD8 T-cell responses was measured as described previously. 33 Briefly, splenocytes were either loaded with 1 mg/mL peptide or left untouched before being labeled with CFSE at different concentrations (10 and 1 mmol/L, respectively).
Equal numbers of the two populations were mixed and injected i.v. into mice. 18-48 h later, splenocytes from the recipients were analyzed by flow cytometer to assess the peptide-specific killing. The ovalbumin-specific lysis was calculated as follows: r = % CFSE low / % CFSE high and % lysis = [1 -(r unprimed / r primed )] ¾ 100, where r is the ratio.
L. monocytegenes infection and tumor challenge. C57BL/6 mice were vaccinated with the indicated cellular vaccine (day 0) before they were i.v. challenged with 5 ¾ 10 4 live L. monocytogenes expressing OVA (day 10). Three days after the bacterial challenge, bacterial burden in spleen and liver was measured by culturing serially diluted homogenized spleen and liver on brain-heart infusion agar plate. Peptide-specific IFNc-secreting cells in PBMC were measured after restimulation with SIINFEKL in the presence of Golgi-Plug for 5 h followed by intracellular staining of IFNc. In a tumor challenge model, mice vaccinated with indicated cellular vaccines were i.v. challenged with live 2 ¾ 10 5 B16-OVA 10 d after vaccination. Two weeks after the tumor challenge, tumor foci in the lung were counted and OVA-specific CD8 T cells were measured after staining with PE-conjugated OT-I tetramer in combination with FITC-conjugated anti-CD8 Ab. To test protective antitumor effect by autologous vaccine, aGC loaded EG-7 cells were irradiated before i.v. vaccination (1x10 6 cells). At 7 d later, mice were s.c. challenged 1 ¾ 10 6 live EG-7 cells and then the survival and tumor size of mice were monitored. To deplete CD8 T cells, 100 mg of anti-CD8 mAb (563.8) was i.p. injected twice (on day-3 and -1) into the mice vaccinated with EG-7/aGC on day-7. On day 0, mice were i.v. challenged with 1 ¾ 10 6 live EG-7 cells and the survival and tumor volume were monitored. Tumor volume based on caliper measurements were calculated by the modified ellipsoidal formula, 1/2(Length ¾ Width 2 ). Statistics. Statistical values were assessed by the Student's t-test. P values were expressed and error bars are SE. The correlation of tumor volume was analyzed for significance using 2-way analysis of variance (ANOVA).The Kaplan-Meier method was used to estimate the survival outcomes and groups were compared with log-rank statistic.
